China, Sept. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Low-Dose Immune Checkpoint Inhibitors Combined with Irinotecan for Third-Line Treatment of Advanced Gastric Cancer'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600133586
Registration Time: 2026/09/29
Type: Interventional study
Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343528
Published by HT Digital Content Services with permission from Health Daily Digest....